JAK1 and COVID-19: Our dataset supports previous COVID-19 drug repurposing studies and can increase the confidence in certain drugs consistently proposed for repurposing, including the JAK1 inhibitor Baricitinib [85], retinoic acid receptor agonist Acitretin [86], and ATPase inhibitors digoxin and ouabain [87].